Investment
Features
FeesSafety
Academy
More
Pluang+

Regeneron partners with Parabilis, investing $125M to develop new antibody-peptide therapies targeting tough diseases.

Company Fundamentals
18 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Regeneron Pharmaceuticals has entered a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapy class aimed at difficult-to-treat targets. Regeneron will invest $125 million upfront and potentially up to $2.2 billion in milestones, combining its antibody technology with Parabilis' Helicon peptide platform. This partnership aims to create new treatments by delivering Helicon peptides inside cells to modulate previously undruggable proteins. Regeneron will handle development, manufacturing, and commercialization of resulting therapies, advancing innovation across multiple disease areas.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App